Security
Oncotelic Therapeutics, Inc. Common Stock · OTLC
OTLCOTCCommon stockCurrentCIK 908259Updated Nov 2, 2026
Name history
MATEON THERAPEUTICS INC · through Mar 26, 2021OXIGENE INC · through Jun 3, 2016
OTLC price & chart
Loading TradingView…
OTC:OTLC on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. After the acquisition of Mateon Therapeutics, Inc through a reverse merger in 2019, we realigned the company pipeline to focus on various cancers, including but not limited to rare pediatric cancers. The United States Food and Drug Administration (“FDA”) has granted us Rare Pediatric Designations (“RPD”) for pediatric Diffuse Intrinsic Pontine Glioma (“DIPG”) for OT-101, which was transferred to our joint venture as part of the joint venture agreement (see “JV” below), pediatric melanoma for CAP4 and acute myeloid leukemia (“AML”) for Oxi4503. In addition, the Company, through it’s JV, is developing 5 additional products for treatments of various cancers. Each of the products being developed by the JV has the potential of becoming very successful drugs. The JV is contemplating developing and obtaining regulatory approval for each of the 5 additional products via different regulatory pathways and in various countries and regions. Further, the Company aims to capitalize on a voucher p…
In the news
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies ↗
Seeking Alpha
Oncotelic Therapeutics GAAP EPS of $0.59 ↗
SEC disclosures
Oncotelic Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
D filing
Items 06b
Show 5 more recent filings
Other Events
Items 8.01, 9.01
Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 3.02, 5.02, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities
Items 1.01, 2.01, 3.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 28,156,163Source | 26,782,245Source | 394,750,732Source | 26,680,807Source | 29,935,173Source | 393,955,039Source | 26,668,208Source | 29,974,410Source | 393,088,242Source | 26,677,426Source | 30,014,952Source | 36,116,819Source |
| GoodwillUSD | 2,788,230Source | 2,788,230Source | 2,788,230Source | 2,788,230Source | 5,988,230Source | 2,788,230Source | 2,788,230Source | 5,988,230Source | 2,788,230Source | 2,788,230Source | 5,988,230Source | 12,071,376Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 409,000Source | 149,018Source | — | 88,022Source | 72,216Source | — | 79,173Source | 188,989Source | — | — | 170,405Source | 241,452Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,976Source | 18,976Source | 2,058Source | 18,976Source | 18,976Source | 2,058Source | 18,976Source | 18,976Source | 51,324Source | 18,976Source | 18,976Source | 19,748Source |
| Assets, CurrentUSD | 1,612,948Source | 239,030Source | 1,460,742Source | 137,592Source | 191,958Source | 2,065,049Source | 124,993Source | 231,195Source | 1,198,252Source | 134,211Source | 271,737Source | 303,164Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 1,252,670Source | — | — | 1,979,377Source | — | — | 1,038,071Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 20,079,663Source | 18,650,273Source | 131,311,353Source | 19,286,912Source | 18,431,550Source | 131,743,498Source | 19,484,762Source | 18,725,020Source | 131,356,683Source | 19,199,914Source | 18,403,415Source | — |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | 509Source | — | — | 509Source | — | — | 244Source | — | — | — |
| Common Stock, Value, IssuedUSD | 4,394,463Source | 4,072,899Source | 4,570,125Source | 4,082,927Source | 4,072,899Source | 4,441,970Source | 4,082,927Source | 3,996,839Source | 4,425,968Source | 4,072,899Source | 3,991,839Source | 3,918,469Source |
| Additional Paid in CapitalUSD | 43,765,008Source | 42,219,400Source | 50,556,882Source | 42,279,570Source | 42,219,400Source | 49,798,210Source | 42,279,570Source | 41,763,054Source | 47,095,219Source | 42,219,400Source | 41,655,026Source | 41,416,632Source |
| Retained Earnings (Accumulated Deficit)USD | -39,108,893Source | -37,439,735Source | 209,433,535Source | -38,061,528Source | -34,135,249Source | 209,045,388Source | -38,339,384Source | -33,925,412Source | 211,239,164Source | -38,040,668Source | -33,516,736Source | -25,926,069Source |
| Stockholders' Equity Attributable to ParentUSD | 9,050,578Source | 8,852,564Source | 264,561,051Source | 8,300,969Source | 12,157,050Source | 263,286,077Source | 8,023,113Source | 11,834,481Source | 262,760,595Source | 8,251,631Source | 12,130,129Source | 19,409,032Source |
| Liabilities and EquityUSD | 28,156,163Source | 26,782,245Source | 394,750,732Source | 26,680,807Source | 29,935,173Source | 393,955,039Source | 26,668,208Source | 29,974,410Source | 393,088,242Source | 26,677,426Source | 30,014,952Source | 36,116,819Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 20,079,663Source | 16,357,380Source | 17,906,958Source | 19,286,912Source | 16,204,434Source | 18,403,989Source | 19,484,762Source | 16,512,247Source | 18,143,278Source | 19,199,914Source | 16,504,947Source | 16,923,407Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 1,735,764Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -974,078Source | -720,592Source | -1,121,672Source | -907,074Source | -653,427Source | -1,074,536Source | -839,667Source | -585,091Source | -1,029,036Source | -774,119Source | -518,592Source | -215,620Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 775,100Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 111,550,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -1,114,369Source | -3,371,651Source | 341,011Source | 210,449Source | -2,239,276Source | -364,264Source | 249,024,915Source | -4,779,459Source | -8,206,065Source | 4,676,603Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,641,847Source | — | 2,378,836Source | — | — | 902,141Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 111,550,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -342,243Source | -166,955Source | -1,383,145Source | -740,267Source | -1,321,047Source | -1,452,562Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 317,000Source | 160,000Source | 1,385,874Source | 656,000Source | 1,250,000Source | 1,125,245Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -25,243Source | -6,955Source | 2,729Source | -84,267Source | -71,047Source | -327,317Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 118,683Source | 94,773Source | 369,983Source | 365,940Source | 390,561Source | 397,995Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,600Source | 1,600Source | 1,600Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 900,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 19,900Source | — | — | — | 0Source | 38,000Source | 112,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 145,583Source | 38,906Source | 198,053Source | 122,141Source | 301,917Source | 1,975,501Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 12,841Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | -392,058Source | 114,722Source | 102,868Source | 484,198Source | -90,080Source | -59,367Source | 353,572Source | -280,402Source | -225,074Source | 142,150Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | 300,000Source | — | — | — | — | — | 12,706Source | — |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 800,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 365,346,775Source | — | 12,706Source | — |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | 365,346,775Source | — | 12,706Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -1,058,976Source | -88,258Source | -373,142Source | -257,810Source |
| General and Administrative ExpenseUSD | — | — | 490,547Source | 80,277Source | 1,093,220Source | 65,672Source | 1,852,590Source | 100,803Source | 3,182,242Source | 376,013Source | 573,726Source | 4,853,664Source |
| GoodwillUSD | — | — | 2,788,230Source | 2,788,230Source | 2,788,230Source | 2,788,230Source | 2,788,230Source | 2,788,230Source | 2,788,230Source | 2,788,230Source | 5,988,230Source | 12,071,376Source |
| Goodwill, Impairment LossUSD | — | — | — | 3,200,000Source | — | — | — | — | — | 3,200,000Source | 6,083,146Source | 4,111,079Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 111,550,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,047,365Source | -3,304,486Source | 388,147Source | 277,856Source | -2,193,776Source | -298,716Source | 249,279,832Source | -4,523,932Source | -7,903,093Source | 5,094,981Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -67,004Source | -67,165Source | -47,136Source | -67,407Source | -45,500Source | -65,548Source | -254,917Source | -255,527Source | -302,972Source | -418,378Source |
| Nonoperating Income (Expense)USD | — | — | -623,396Source | -90,894Source | 1,184,576Source | 276,418Source | -385,891Source | -263,164Source | 363,761,514Source | -1,203,446Source | -1,558,050Source | 14,398,256Source |
| Operating ExpensesUSD | — | — | 490,973Source | 3,280,757Source | 1,093,565Source | 65,969Source | 1,853,385Source | 101,100Source | 3,186,599Source | 3,576,013Source | 6,718,015Source | 9,721,653Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | 6,630Source | — | — | — | — | — | — | 158,820Source |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 250,000Source | — | — | — | — | — | 70,000Source | — |
| Operating Income (Loss)USD | — | — | -490,973Source | -3,280,757Source | -843,565Source | -65,969Source | -1,853,385Source | -101,100Source | -3,186,599Source | -3,576,013Source | -6,648,015Source | -9,721,653Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 360,574,915Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 111,550,000Source | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -67,004Source | -67,165Source | -47,136Source | -67,407Source | -45,500Source | -65,548Source | -254,917Source | -255,527Source | -302,972Source | -418,378Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,047,365Source | -3,304,486Source | 388,147Source | 277,856Source | -2,193,776Source | -298,716Source | 249,279,832Source | -4,523,932Source | -7,903,093Source | 5,094,981Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | -0.01Source | 0Source | 0Source | 0Source | 0Source | 0.59Source | -0.01Source | -0.02Source | 0.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -0.01Source | 0Source | 0Source | 0Source | 0Source | 0.59Source | — | -0.02Source | 0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 426,435,213Source | 407,289,888Source | 447,386,505Source | 408,292,720Source | 443,801,416Source | 407,423,329Source | 421,045,524Source | 404,396,473Source | 396,165,575Source | 384,075,369Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 407,289,888Source | 467,914,165Source | 452,809,058Source | 443,801,416Source | 407,423,329Source | 422,234,747Source | — | 396,165,575Source | 457,299,890Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 12,841Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 365,346,775Source | — | 12,706Source | — |
| General and Administrative ExpenseUSD | — | — | 490,547Source | 80,277Source | 1,093,220Source | 65,672Source | 1,852,590Source | 100,803Source | 3,182,242Source | 376,013Source | 573,726Source | 4,853,664Source |
| Goodwill, Impairment LossUSD | — | — | — | 3,200,000Source | — | — | — | — | — | 3,200,000Source | 6,083,146Source | 4,111,079Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,044,786Source | 2,971,046Source |
| Nonoperating Income (Expense)USD | — | — | -623,396Source | -90,894Source | 1,184,576Source | 276,418Source | -385,891Source | -263,164Source | 363,761,514Source | -1,203,446Source | -1,558,050Source | 14,398,256Source |
| Operating ExpensesUSD | — | — | 490,973Source | 3,280,757Source | 1,093,565Source | 65,969Source | 1,853,385Source | 101,100Source | 3,186,599Source | 3,576,013Source | 6,718,015Source | 9,721,653Source |
| Research and Development ExpenseUSD | — | — | — | 480Source | 345Source | 297Source | 795Source | 297Source | 4,357Source | — | 61,143Source | 756,910Source |
| Interest Expense (non-operating) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-291724
Filing attachments
ex99-1.htm · 8-K · 2026-04-16
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) - Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, as well as antisense and small molecule injectable drugs for the treatment of cancer, today announced it…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-02
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform Los Angeles, CA - April 2, 2026 - Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today announced that it has entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercializati…
Read attachment ↗